Chapter/Section Purchase

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Liver Transplantation Operation
1.2.3 UDCA Drugs
1.2.4 PSC Drugs
1.3 Market by Application
1.3.1 Global Primary Sclerosing Cholangitis Treatment Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Primary Sclerosing Cholangitis Treatment Market Perspective (2017-2028)
2.2 Primary Sclerosing Cholangitis Treatment Growth Trends by Region
2.2.1 Primary Sclerosing Cholangitis Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Primary Sclerosing Cholangitis Treatment Historic Market Size by Region (2017-2022)
2.2.3 Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Region (2023-2028)
2.3 Primary Sclerosing Cholangitis Treatment Market Dynamics
2.3.1 Primary Sclerosing Cholangitis Treatment Industry Trends
2.3.2 Primary Sclerosing Cholangitis Treatment Market Drivers
2.3.3 Primary Sclerosing Cholangitis Treatment Market Challenges
2.3.4 Primary Sclerosing Cholangitis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Primary Sclerosing Cholangitis Treatment Players by Revenue
3.1.1 Global Top Primary Sclerosing Cholangitis Treatment Players by Revenue (2017-2022)
3.1.2 Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Primary Sclerosing Cholangitis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Primary Sclerosing Cholangitis Treatment Revenue
3.4 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio
3.4.1 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Sclerosing Cholangitis Treatment Revenue in 2021
3.5 Primary Sclerosing Cholangitis Treatment Key Players Head office and Area Served
3.6 Key Players Primary Sclerosing Cholangitis Treatment Product Solution and Service
3.7 Date of Enter into Primary Sclerosing Cholangitis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Primary Sclerosing Cholangitis Treatment Breakdown Data by Type
4.1 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Type (2017-2022)
4.2 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Type (2023-2028)
5 Primary Sclerosing Cholangitis Treatment Breakdown Data by Application
5.1 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Application (2017-2022)
5.2 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Primary Sclerosing Cholangitis Treatment Market Size (2017-2028)
6.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022)
6.3 North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Primary Sclerosing Cholangitis Treatment Market Size (2017-2028)
7.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022)
7.3 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size (2017-2028)
8.2 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022)
8.3 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Primary Sclerosing Cholangitis Treatment Market Size (2017-2028)
9.2 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022)
9.3 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size (2017-2028)
10.2 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022)
10.3 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Allergan
11.1.1 Allergan Company Detail
11.1.2 Allergan Business Overview
11.1.3 Allergan Primary Sclerosing Cholangitis Treatment Introduction
11.1.4 Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.1.5 Allergan Recent Development
11.2 Glenmark
11.2.1 Glenmark Company Detail
11.2.2 Glenmark Business Overview
11.2.3 Glenmark Primary Sclerosing Cholangitis Treatment Introduction
11.2.4 Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.2.5 Glenmark Recent Development
11.3 Impax Laboratories
11.3.1 Impax Laboratories Company Detail
11.3.2 Impax Laboratories Business Overview
11.3.3 Impax Laboratories Primary Sclerosing Cholangitis Treatment Introduction
11.3.4 Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.3.5 Impax Laboratories Recent Development
11.4 Mylan
11.4.1 Mylan Company Detail
11.4.2 Mylan Business Overview
11.4.3 Mylan Primary Sclerosing Cholangitis Treatment Introduction
11.4.4 Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.4.5 Mylan Recent Development
11.5 Teva Pharmaceuticals
11.5.1 Teva Pharmaceuticals Company Detail
11.5.2 Teva Pharmaceuticals Business Overview
11.5.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.5.4 Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.5.5 Teva Pharmaceuticals Recent Development
11.6 Dr. Falk Pharma
11.6.1 Dr. Falk Pharma Company Detail
11.6.2 Dr. Falk Pharma Business Overview
11.6.3 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.6.4 Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.6.5 Dr. Falk Pharma Recent Development
11.7 Daewoong Pharmaceutical
11.7.1 Daewoong Pharmaceutical Company Detail
11.7.2 Daewoong Pharmaceutical Business Overview
11.7.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Introduction
11.7.4 Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.7.5 Daewoong Pharmaceutical Recent Development
11.8 Epic Pharma
11.8.1 Epic Pharma Company Detail
11.8.2 Epic Pharma Business Overview
11.8.3 Epic Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.8.4 Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.8.5 Epic Pharma Recent Development
11.9 Mitsubishi Tanabe Pharma
11.9.1 Mitsubishi Tanabe Pharma Company Detail
11.9.2 Mitsubishi Tanabe Pharma Business Overview
11.9.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.9.4 Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.9.5 Mitsubishi Tanabe Pharma Recent Development
11.10 Lannett
11.10.1 Lannett Company Detail
11.10.2 Lannett Business Overview
11.10.3 Lannett Primary Sclerosing Cholangitis Treatment Introduction
11.10.4 Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.10.5 Lannett Recent Development
11.11 Bruschettini
11.11.1 Bruschettini Company Detail
11.11.2 Bruschettini Business Overview
11.11.3 Bruschettini Primary Sclerosing Cholangitis Treatment Introduction
11.11.4 Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.11.5 Bruschettini Recent Development
11.12 Shanghai Pharma
11.12.1 Shanghai Pharma Company Detail
11.12.2 Shanghai Pharma Business Overview
11.12.3 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.12.4 Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.12.5 Shanghai Pharma Recent Development
11.13 Grindeks
11.13.1 Grindeks Company Detail
11.13.2 Grindeks Business Overview
11.13.3 Grindeks Primary Sclerosing Cholangitis Treatment Introduction
11.13.4 Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.13.5 Grindeks Recent Development
11.14 Acorda Therapeutics
11.14.1 Acorda Therapeutics Company Detail
11.14.2 Acorda Therapeutics Business Overview
11.14.3 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Introduction
11.14.4 Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.14.5 Acorda Therapeutics Recent Development
11.15 Gilead Sciences
11.15.1 Gilead Sciences Company Detail
11.15.2 Gilead Sciences Business Overview
11.15.3 Gilead Sciences Primary Sclerosing Cholangitis Treatment Introduction
11.15.4 Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.15.5 Gilead Sciences Recent Development
11.16 Intercept Pharmaceuticals
11.16.1 Intercept Pharmaceuticals Company Detail
11.16.2 Intercept Pharmaceuticals Business Overview
11.16.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.16.4 Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.16.5 Intercept Pharmaceuticals Recent Development
11.17 Shire Plc
11.17.1 Shire Plc Company Detail
11.17.2 Shire Plc Business Overview
11.17.3 Shire Plc Primary Sclerosing Cholangitis Treatment Introduction
11.17.4 Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.17.5 Shire Plc Recent Development
11.18 NGM Biopharmaceuticals
11.18.1 NGM Biopharmaceuticals Company Detail
11.18.2 NGM Biopharmaceuticals Business Overview
11.18.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.18.4 NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.18.5 NGM Biopharmaceuticals Recent Development
11.19 Conatus Pharmaceuticals
11.19.1 Conatus Pharmaceuticals Company Detail
11.19.2 Conatus Pharmaceuticals Business Overview
11.19.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.19.4 Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.19.5 Conatus Pharmaceuticals Recent Development
11.20 Durect Corporation
11.20.1 Durect Corporation Company Detail
11.20.2 Durect Corporation Business Overview
11.20.3 Durect Corporation Primary Sclerosing Cholangitis Treatment Introduction
11.20.4 Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.20.5 Durect Corporation Recent Development
11.21 Sirnaomics
11.21.1 Sirnaomics Company Detail
11.21.2 Sirnaomics Business Overview
11.21.3 Sirnaomics Primary Sclerosing Cholangitis Treatment Introduction
11.21.4 Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.21.5 Sirnaomics Recent Development
11.22 Shenzhen HighTide Biopharmaceuticals
11.22.1 Shenzhen HighTide Biopharmaceuticals Company Detail
11.22.2 Shenzhen HighTide Biopharmaceuticals Business Overview
11.22.3 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.22.4 Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.22.5 Shenzhen HighTide Biopharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details